By David Wallace – September 1, 2026 The U.S. Food and Drug Administration approved Mimrylo™ (mim-rahy-loh), the brand name for rusfertide, on August 28, 2026, for the treatment of erythrocytosis in adults with polycythemia vera (PV). Erythrocytosis means the body is making too many red blood cells. Mimrylo is the first FDA-approved hepcidin mimetic for […]
Divesiran Cuts Phlebotomy Need in Phase 2 PV Trial
By David Wallace Silence Therapeutics reported that divesiran met the primary endpoint of the randomized Phase 2 SANRECO trial. Among 48 phlebotomy-dependent polycythemia vera patients, 88% of those receiving divesiran maintained hematocrit below 45% without phlebotomy during weeks 18 through 36, compared with 19% on placebo. The difference was statistically significant. What the Phase 2 […]
Beta-Alanine for PV Related Itching: A Potential Solution
by David Wallace For many people living with polycythemia vera (PV) and other myeloproliferative neoplasms, stepping into a warm shower can trigger an unbearable sensation that has nothing to do with the water temperature. Aquagenic pruritus (intense itching that occurs after contact with water) remains one of the most frustrating symptoms patients face, affecting nearly […]
Polycythemia Vera Brain Fog
by David Wallace updated July 10, 2025 This is no wonderful “epiphany moment” article, just a quick report on a real myeloproliferative neoplasm (MPN) symptom I experience from time to time. Many mornings, I make a healthy smoothie to get me up and rolling. This morning I grabbed the wrong ingredient and sprinkled it in […]
